Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial.
about
Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agentsThe Role of Invariant Natural Killer T Cells in Dendritic Cell Licensing, Cross-Priming, and Memory CD8(+) T Cell GenerationAntiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferonAdoptive T Cell Therapy Targeting CD1 and MR1Stages versus subsets: Invariant Natural Killer T cell lineage differentiationA glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primatesImmune therapy for hepatitis BRestored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis BInvariant NKT cells: regulation and function during viral infection.Designing immune therapy for chronic hepatitis B.The split personality of NKT cells in malignancy, autoimmune and allergic disordersColocalization of a CD1d-Binding Glycolipid with a Radiation-Attenuated Sporozoite Vaccine in Lymph Node-Resident Dendritic Cells for a Robust Adjuvant Effect.Preserved Function of Circulating Invariant Natural Killer T Cells in Patients With Chronic Hepatitis B Virus InfectionNatural killer and natural killer T cells in liver fibrosisNKT cell costimulation: experimental progress and therapeutic promiseInvariant natural killer T cells: bridging innate and adaptive immunity.The bovine CD1D gene has an unusual gene structure and is expressed but cannot present α-galactosylceramide with a C26 fatty acidNatural killer T cells in health and disease.Invariant NKT cell activation induces neutrophil accumulation and hepatitis: opposite regulation by IL-4 and IFN-γToll-like receptor agonists and alpha-galactosylceramide synergistically enhance the production of interferon-gamma in murine splenocytes.The invariant NKT cell subset in anti-viral defenses: a dark horse in anti-influenza immunity?Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens.Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.Targeting the diverse immunological functions expressed by hepatic NKT cells.Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides.Dengue virus infection: current concepts in immune mechanisms and lessons from murine models.Optimizing NKT cell ligands as vaccine adjuvantsImmunopathogenesis of chronic hepatitis B.Exploring the Therapeutic Potentials of iNKT Cells for Anti-HBV Treatment.The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation.Novel insights into immunotherapy for hepatitis B patients.Glycolipid activators of invariant NKT cells as vaccine adjuvants.Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.Engagement of glycosylphosphatidylinositol-anchored proteins results in enhanced mouse and human invariant natural killer T cell responses.The dynamic changes of circulating invariant natural killer T cells during chronic hepatitis B virus infection.PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication.T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection.Program Cell Death Receptor-1-Mediated Invariant Natural Killer T-Cell Control of Peritoneal Macrophage Modulates Survival in Neonatal Sepsis.In-vivo stimulation of macaque natural killer T cells with α-galactosylceramide.Tim-3 blockade promotes iNKT cell function to inhibit HBV replication.
P2860
Q26748456-89194734-3686-46B1-B42A-E95BB256D483Q26797344-AA94836C-7C29-417C-A913-1770C3DB7D00Q26830435-976D1F2C-B84E-4702-8DB9-EA64ED2F33A7Q26998503-9367CD5D-4C44-41A7-A107-4CC4D3874684Q27003411-B621DF7A-7D1D-4BD9-9767-8CC33AE9B016Q27303293-B47828E4-8B7E-442A-BAF6-6A48FC3BED7DQ28078856-F4C099F8-1654-42E1-8E69-DC71C715F966Q28741248-B0CF3C10-0729-47A5-A198-C86805E4D361Q34390484-3A02B87B-0E7C-4BC6-812D-0F09E03BE487Q34825732-0D6FA5DD-FC7A-4293-8273-4B21CAE642C7Q35590727-A9BAFA44-92AB-4C0D-B179-980FACC70D6BQ36031556-3907F7EE-1A3C-420D-8870-A3B705E0E15BQ36194477-F8C453C2-D10E-497E-A125-DEB702232B34Q36553227-EFECA912-F86A-4578-B4D2-BCDC2185D562Q36739843-8500283D-17DF-481C-9DCE-015EE49FC7A5Q36739848-21D98A20-138F-41B8-BF1A-02F04F8F47A5Q36749511-4C2A327F-553B-40C2-9F3A-9D66F96845DBQ36765720-BBBBB09E-BB19-4A45-95BB-78370BA289FFQ37136334-32135887-3A86-41C2-B53F-6936D310A00CQ37137098-9897607A-D979-4D79-BEAF-79B9AA284577Q37762343-685AC6B6-B946-4D71-8B4C-A3E721839B0BQ37822744-E943EA88-151C-4191-AFC6-1ED4C5339FF7Q37824065-3F17A596-491A-42A4-A86C-FE52935FC640Q37874633-94DC05E6-F61A-4346-A7AD-2AA66F7D50D5Q38098583-A4775B97-9A6A-4576-B357-665C1EDB0092Q38158411-28EC78FD-54B5-497B-AB88-57632C70F312Q38206819-F03A3AD7-0B4C-4A18-B6D1-FE4A364E47D6Q38262108-7CB54887-D352-4EAF-A9BA-AD3B6C1EAD80Q38273315-C287FB98-C6F0-457E-BA88-0AE1091329B0Q38535876-235E55DF-13F9-464F-AA66-D4E4A026B4E0Q38655228-A24FFD09-945B-401D-8DD5-D121B96A2C3AQ38885794-07297D3A-D918-4460-BCC6-B665DF4F715AQ39196835-7CE97528-26A1-4D9B-8A5F-D6311A30834DQ39633103-C8DEA13F-7CE4-4FE2-BAC3-7CE8A2D0BEB5Q40774067-AEB29AC9-54FF-4BAB-ABC7-C7175828DF71Q42271423-8268F53D-7B1F-4B03-B3A1-A31A1BFF310AQ43182638-87BC6AF4-20D3-45F8-B4CA-197F25C54EB2Q47160878-7125B3EC-8E72-4287-9F98-B62907DE87C5Q51875279-E9821CDF-E7D1-45BF-8A42-890578D99103Q54965814-3CA71996-99B2-4995-8911-E97AB6ABAF6B
P2860
Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Alpha-galactosylceramide in ch ...... o-controlled Phase I/II trial.
@en
type
label
Alpha-galactosylceramide in ch ...... o-controlled Phase I/II trial.
@en
prefLabel
Alpha-galactosylceramide in ch ...... o-controlled Phase I/II trial.
@en
P2093
P921
P356
P1433
P1476
Alpha-galactosylceramide in ch ...... bo-controlled Phase I/II trial
@en
P2093
Andrea M Woltman
B Mary E von Blomberg
Dave Sprengers
Harry L A Janssen
Kunihiko Hayashi
Nobusuke Nishi
Rekha S Binda
Renate van der Molen
Rik J Scheper
P304
P356
10.3851/IMP1295
P577
2009-01-01T00:00:00Z